Fourth-generation CAR-T cells secreting transgenic IL-7, IL-12, IL-15, and IL-18 have been shown, in preclinical trials with solid tumors, to enhance T-cell activation and stimulate the recruitment of innate immunity cells to kill antigen-negative cancer cells in the lesion focus. The gene discussed is IL15; the disease is cancer.